Schattenberg, Jörn M.

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

Govaere, O., Hasoon, M., Alexander, L., Cockell, S., Tiniakos, D., Ekstedt, M., Schattenberg, J. M., Boursier, J., Bugianesi, E., Ratziu, V., et al. (2023) · Nature Metabolism

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 178

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study

Isokuortti, E., Zhou, Y., Peltonen, M., Bugianesi, E., Clement, K., Bonnefont-Rousselot, D., Lacorte, J.-M., Gastaldelli, A., Schuppan, D., Schattenberg, J. M., et al. (2017) · Diabetologia

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 120

Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum

Glass, O., Filozof, C., Noureddin, M., Berner-Hansen, M., Schabel, E., Omokaro, S. O., Schattenberg, J. M., Barradas, K., Miller, V., Francque, S., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 89

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Traussnigg, S., Schattenberg, J. M., Demir, M., Wiegand, J., Geier, A., Teuber, G., Hofmann, W. P., Kremer, A. E., Spreda, F., Kluwe, J., et al. (2019) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 88

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 63

A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients

Eslam, M., Wong, G. L.-H., Hashem, A. M., Chan, H. L.-Y., Nielsen, M. J., Leeming, D. J., Chan, A. W.-H., Chen, Y., Duffin, K. L., Karsdal, M., et al. (2021) · American Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 53

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 28

OS-124 Identification and validation of pre-identified morphological baseline features for prediction of fibrosis progression in MAESTRO-NASH

Harrison, S. A., Taub, R., Labriola, D., Zhang, H., Chng, E., Ren, Y., Tai, D., & Schattenberg, J. M. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 3

WED-263 A machine learning approach to identify patient features associated with metabolic dysfunction-associated steatohepatitis from the United Kingdom biobank

Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., Karamchandani, U., Romero, J., Henstock, P., Emir, B., & Sanyal, A. J. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare

Cited by 1

SAT-214 Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)

Schattenberg, J. M., Anstee, Q. M., Harrison, S. A., Noureddin, M., Taub, R., Labriola, D., Priel, J., & Padmanabhan, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 1